Review3 Biotech2022
Distribution, biosynthesis and therapeutic potential of lignans.
Review in 3 Biotech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Antioxidants in Plant-Based Food Matrices: From Structure-Activity and Degradation Kinetics to Formulation Design.Comprehensive reviews in food science and food safety · 2026Review
- Protein-Polyphenol Interactions in Specialty Oilseeds: Multiscale Mechanisms, Physicochemical Reshaping, and Advanced Food Applications.Foods (Basel, Switzerland) · 2026Review
- Association of lignan metabolites with prevalent stroke and mortality in stroke patients: results from NHANES.Journal of clinical biochemistry and nutrition · 2026Article
- Molecular Mechanisms of Lignans in Lowering Blood Pressure and Anti-Obesity Effects: A Review.Foods (Basel, Switzerland) · 2026Review
- An Analysis of Effective Components of Pulsatillae radix Using UHPLC-QTOF- MS/MS and Network Pharmacology to Investigate its Effects on Ulcerative Colitis.Combinatorial chemistry & high throughput screening · 2026Article
- Phytochemicals: Principles and Practice.Biology · 2025Review
- Assessment of Neolignan Profiles during the Growth Period ofACS omega · 2025Article
- Dietary Polyphenols-Gut Microbiota Interactions: Intervention Strategies and Metabolic Regulation for Intestinal Diseases.Biology · 2025Review
- Optimization of the Extraction of Bioactive Compounds and Metabolomic Profile ofPlants (Basel, Switzerland) · 2025Article
- Unlocking Polyphenol Efficacy: The Role of Gut Microbiota in Modulating Bioavailability and Health Effects.Nutrients · 2025Review
- Unveiling a novel ellagic acid derivative as a potent lipoxygenase (LOX) inhibitor: integration of computational modeling and experimental validation.Journal of computer-aided molecular design · 2025Article
- Antioxidant profiling and quality assessment of Lithocarpus polystachyus sweet tea using LC-ECD and LC-MS/MS.Scientific reports · 2025Article
- Flaxseed in Diet: A Comprehensive Look at Pros and Cons.Molecules (Basel, Switzerland) · 2025Review
- Antimicrobial Potential of Polyphenols: Mechanisms of Action and Microbial Responses-A Narrative Review.Antioxidants (Basel, Switzerland) · 2025Review
- Natural strategies to optimize estrogen levels in aging women: mini review.Frontiers in aging · 2025Review
- Research progress on the use of polyphenols in the treatment of Crohn's disease.Frontiers in pharmacology · 2025Review
- Therapeutic Potential of Resveratrol and Lignans in the Management of Tuberculosis.Cell biochemistry and biophysics · 2024Review
- Secoisolariciresinol diglucoside attenuates neuroinflammation and cognitive impairment in female Alzheimer's disease mice via modulating gut microbiota metabolism and GPER/CREB/BDNF pathway.Journal of neuroinflammation · 2024Article
- Sesame Seeds: A Nutrient-Rich Superfood.Foods (Basel, Switzerland) · 2024Review
- Impact of Pulmonary microbiota on lung cancer treatment-related pneumonia.Journal of Cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lignans have long been known for their abundant therapeutic properties due to their polyphenolic structure. Linseed is the richest plant source of lignans and has been studied widely for their properties. The most prevalent lignan, secoisolariciresinol diglucoside (SDG), is consumed with linseed and converted into mammalian lignans, enterodiol (END) and enterolactone (ENL), by the gut microbiota. SDG can easily be assessed using HPLC and its deglycosylated form viz secoisolariciresinol can be asses using GC-MS techniques. Variety of extraction and analysis methods has been reported for plant lignans. SDG is known to have therapeutic properties including anti-oxidant, anti-cancerous, anti-inflammatory, modulation of gene expression, anti-diabetic, estrogenic and anti-estrogenic. Despite a large number of bioactivities, strong evidences for the underlying mechanisms for most of the properties are still unknown. SDG is most studied for its anti-cancerous properties. But the use of lignans as anti-carcinogenic agent is limited and commercially not reported due to challenges of purification at commercial level, rapid metabolism, untargeted delivery and toxic compounds associated with lignans. Exploration of more prominent and active derivatives of SDG and their targeted drug delivery should be an important research toward the use of bioactive lignans of linseed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.